BioPharma Resources

Drugs by condition

Drugs approved for multiple sclerosis

Brand-name prescription drugs and biologics whose FDA label lists multiple sclerosis as an approved use. Matched on the label phrases: "multiple sclerosis".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

40

Still marketed, NDA or BLA

Drug classes

13

Novel drugs

21

New molecular entities and new biologics

In development

30

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for multiple sclerosis.

  • Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) · Genentech INC Sep 13, 2024
  • Tyruko (Natalizumab-Sztn) · Sandoz INC Aug 24, 2023
  • Briumvi (Ublituximab-Xiiy) · Tg Therapeutics, INC NovelDec 28, 2022
  • Tascenso Odt (Fingolimod Lauryl Sulfate) · Cycle Dec 9, 2022
  • Fleqsuvy (Baclofen) · Azurity Feb 4, 2022

All approved drugs for multiple sclerosis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 170 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

CD20-directed Cytolytic Antibody (4)

  • Briumvi Ublituximab-Xiiy · Tg Therapeutics, INC · 2022
  • Ocrevus Ocrelizumab · Genentech INC · 2017
  • Kesimpta Ofatumumab · Novartis · 2009
  • Ocrevus Zunovo Ocrelizumab and Hyaluronidase-Ocsq · Genentech INC · 2024

gamma-Aminobutyric Acid-ergic Agonist (4)

Interferon beta (3)

  • Plegridy Peginterferon Beta-1a · Biogen Idec INC · 2014
  • Rebif Interferon Beta-1a · Serono INC · 2002
  • Avonex Interferon Beta-1a · Biogen · 1996

Corticosteroid (3)

  • Medrol Methylprednisolone · Pfizer · 1957
  • Kenalog-40 Triamcinolone Acetonide · Apothecon · 1965
  • Cortef Hydrocortisone · Pharmacia and Upjohn · 1952

Sphingosine 1-phosphate Receptor Modulator (2)

  • Ponvory Ponesimod · Vanda Pharms INC · 2021
  • Mayzent Siponimod · Novartis · 2019

Integrin Receptor Antagonist (2)

  • Tysabri Natalizumab · Biogen Idec · 2004
  • Tyruko Natalizumab-Sztn · Sandoz INC · 2023

Adrenocorticotropic Hormone (2)

Pyrimidine Synthesis Inhibitor (1)

  • Aubagio Teriflunomide · Sanofi Aventis US · 2012

Potassium Channel Blocker (1)

  • Ampyra Dalfampridine · Merz · 2010

CD52-directed Cytolytic Antibody (1)

Acetylcholine Release Inhibitor (1)

Purine Antimetabolite (1)

  • Mavenclad Cladribine · Emd Serono INC · 2019

Class not listed in FDA's data (15)

  • Zeposia Ozanimod Hydrochloride · Bristol · 2020
  • Tecfidera Dimethyl Fumarate · Biogen · 2013
  • Gilenya Fingolimod Hydrochloride · Novartis · 2010
  • Copaxone Glatiramer Acetate · Teva Pharms USA · 1996
  • Betaseron Interferon Beta-1b · Bayer Healthcare Pharms · 1993
  • Dantrium Dantrolene Sodium · Ph Health · 1974
  • Celestone Soluspan Betamethasone Acetate, Betamethasone Sodium Phosphate · Organon · 1965
  • Tascenso Odt Fingolimod Lauryl Sulfate · Cycle · 2022
  • Bafiertam Monomethyl Fumarate · Banner Life Sciences · 2020
  • Vumerity Diroximel Fumarate · Biogen · 2019
  • Orapred Odt Prednisolone Sodium Phosphate · Advanz Pharma · 2006
  • Pediapred Prednisolone Sodium Phosphate · Pai Holdings · 1986
  • Depo-Medrol Methylprednisolone Acetate · Pfizer · 1959
  • Solu-Medrol Methylprednisolone Sodium Succinate · Pharmacia and Upjohn · 1959
  • Solu-Cortef Hydrocortisone Sodium Succinate · Pharmacia and Upjohn · 1955

Drugs in development for multiple sclerosis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • OrelabrutinibICP-022Phase 311 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Mantle Cell Lymphoma, Part 1:r/r B-cell Malignancies, Part 2:B-cell Malignancies

  • FrexalimabSAR441344Phase 39 trials

    Sanofi · Multiple Sclerosis, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion

  • FenebrutinibRO7010939, GDC-0853Phase 36 trials

    Roche (Genentech) · Relapsing Multiple Sclerosis, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive

  • PPV2323-valent Pneumococcal Polysaccharide Vaccine, lot 1Phase 36 trials

    Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease

  • RocbrutinibLP-168, NWP-775Phase 36 trials

    Guangzhou Lupeng Pharmaceutical Company LTD. · Diffuse Large B-Cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Mantle Cell Lymphoma

  • rHuPH20Phase 35 trials

    Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma

  • ObexelimabPhase 34 trials

    Zenas BioPharma (USA), LLC · Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia, Relapsing Multiple Sclerosis

  • IMU-838Vidofludimus calciumPhase 33 trials

    Immunic AG · Relapsing-Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting

  • Sanofi · Multiple Sclerosis

  • TolebrutinibSAR442168Phase 33 trials

    Sanofi · Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis

  • KYV-101Phase 32 trials

    Kyverna Therapeutics · Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis

  • Sanofi · Multiple Sclerosis

  • ABP 692Phase 31 trial

    Amgen · Relapsing-remitting Multiple Sclerosis (RRMS)

  • BCD-281Phase 31 trial

    Biocad · Relapsing-remitting Multiple Sclerosis (RRMS)

  • rapcabtagene autoleucelYTB323Phase 28 trials

    Novartis · Lupus Nephritis, Rheumatoid Arthritis (RA) and Sjögren's Disease (SjD), ANCA Associated Vasculitis (AAV)

  • zamtocabtagene autoleucelMB-CART2019.1Phase 25 trials

    Miltenyi Biomedicine GmbH · CAR T Cell Therapy, Mantle Cell Lymphoma (MCL), Multiple Sclerosis

  • Ever Supreme Bio Technology Co., Ltd. · COVID-19 Infection, Multiple Sclerosis, ST Elevation Myocardial Infarction

  • Zugocabtagene geleucelCTX112Phase 23 trials

    CRISPR Therapeutics AG · B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy

  • Autologous HB-adMSCsPhase 22 trials

    Hope Biosciences LLC · Traumatic Brain Injury, Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis

  • BMS-986368CC-97489Phase 22 trials

    Bristol Myers Squibb · Agitation, Alzheimer Disease, Multiple Sclerosis Spasticity

More on multiple sclerosis: recruiting trials · published research

Related in neurology: Alzheimer's disease · Parkinson's disease · Epilepsy and seizures · Migraine · ALS (amyotrophic lateral sclerosis) · Myasthenia gravis · Spinal muscular atrophy · Duchenne muscular dystrophy · Huntington's disease chorea · Tardive dyskinesia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.